MIRA MIRA Pharmaceuticals, Inc.
USHealthcareAs of 2026-10-09
Why MIRA matters now
MIRA Pharmaceuticals, Inc. (MIRA) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.75 with +6.05% on the session and $31.3M in market capitalization; recent performance reads 1-month +0.25% and YTD -36.93%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-1.2M, and EPS of $-0.03. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -10.6%.
The latest indexable market news headline is "MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is available with a median target of $—; recent insider activity includes Shekhat Denil Nanji filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.27
P/S
0.00
EV/EBITDA
-3.59
DCF Value
$0.26
FCF Yield
-10.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-140.8%
ROA
-103.6%
ROIC
-104.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-1.2M | $-0.03 |
| Q4 2025 | $0.00 | $-6.0M | $-0.14 |
| FY 2025 | $0.00 | $-10.4M | $-1.35 |
| Q3 2025 | $0.00 | $-1.1M | $-1.18 |
Analyst Ratings
Consensus
—
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
1.44
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.